Australia markets close in 2 hours 8 minutes

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.97+0.25 (+3.24%)
At close: 04:00PM EST
8.11 +0.14 (+1.76%)
After hours: 07:36PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.13B
Enterprise value 673.64M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.50k
Price/book (mrq)1.53
Enterprise value/revenue 2.73k
Enterprise value/EBITDA -2.26

Trading information

Stock price history

Beta (5Y monthly) 0.70
52-week change 3-27.17%
S&P500 52-week change 3-8.95%
52-week high 317.49
52-week low 35.41
50-day moving average 37.69
200-day moving average 310.29

Share statistics

Avg vol (3-month) 32.03M
Avg vol (10-day) 32M
Shares outstanding 5144.21M
Implied shares outstanding 6N/A
Float 883.11M
% held by insiders 129.79%
% held by institutions 176.19%
Shares short (12 Jan 2023) 434.16M
Short ratio (12 Jan 2023) 415.48
Short % of float (12 Jan 2023) 437.86%
Short % of shares outstanding (12 Jan 2023) 423.69%
Shares short (prior month 14 Dec 2022) 430.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-126,707.69%

Management effectiveness

Return on assets (ttm)-19.89%
Return on equity (ttm)-36.57%

Income statement

Revenue (ttm)247k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)0.00%
Gross profit (ttm)-181.69M
EBITDA -297.5M
Net income avi to common (ttm)-312.65M
Diluted EPS (ttm)-2.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)552.23M
Total cash per share (mrq)3.83
Total debt (mrq)102.54M
Total debt/equity (mrq)13.86
Current ratio (mrq)11.64
Book value per share (mrq)5.14

Cash flow statement

Operating cash flow (ttm)-203.86M
Levered free cash flow (ttm)-100.65M